Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.67 |
| ▸ | RAB9A | P51151 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ECE2 | P0DPD6 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | DHFR | P00374 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15550642 | 1.00 | NPC1 (0.67) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL16979254 | 0.84 | GLA (0.64) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL15548652 | 0.83 | GLA (0.62) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL15548649 | 0.83 | GLA (0.62) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL16971005 | 0.83 | MEN1 (0.67) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL16971003 | 0.83 | MEN1 (0.67) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL15549369 | 0.81 | MEN1 (0.74) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL15549139 | 0.81 | MEN1 (0.74) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL15549141 | 0.81 | MEN1 (0.74) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL18685678 | 0.81 | GLA (0.60) | NPC1RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300085-A | Alkenyl method of methyl heterocyclic compound | 温州大学 | 2021-02-02 | — | — | CN | disclosed |
| EP-3147280-B1 | ANTI-ANGIOGENIC COMPOUND | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2018-03-07 | — | — | EP | disclosed |
| US-9815788-B2 | Anti-angiogenic compounds | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2017-11-14 | — | — | US | disclosed |
| EP-3147280-A1 | ANTI-ANGIOGENIC COMPOUND | University College Dublin, National University of Ireland, Dublin (IE) | 2017-03-29 | — | — | EP | disclosed |
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2017-02-23 | — | — | US | disclosed |
| EP-2877454-B1 | ANTI-ANGIOGENIC 2-STYRYL-QUINOLINE COMPOUNDS | UNIV DUBLIN (IE) | 2016-11-02 | — | — | EP | disclosed |
| US-9388138-B2 | Anti-angiogenic compounds | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2015-08-06 | — | — | US | disclosed |
| EP-2877454-A1 | ANTI-ANGIOGENIC COMPOUNDS | University College Dublin National University Of Ireland, Dublin (IE) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014012889-A1 | ANTI-ANGIOGENIC COMPOUNDS | UNIVERSITY COLLEGE DUBLIN - NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050930-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | NPC1 2305/4885RAB9A 1336/4885MEN1 4178/4885 |
| US-20150218100-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, VHL | NPC1 2305/4885RAB9A 1336/4885MEN1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.